

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Cheng et al.

Serial No.: To be assigned
(Continuation of Application No.:
08/436,960, filed June 5, 1995)

Group Art Unit: To be Assigned

Filed: September 4, 2003

Examiner: To Be Assigned

For: Method of Treating or Preventing
Hepatitis B Virus

Attorney Docket No.: 6523-038-999

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56 and 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §§ 1.56 and 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the above-identified application that are or may be related to patentability of the claimed invention, Attorneys for Applicants hereby invite the Examiner's attention to references **A01-A18, B01-B28 and C01-C58**, which are listed on the accompanying form PTO-1449 entitled "List of References Cited By Applicant." This application is a continuation of, *inter alia*, application Serial No. 08/463,960, filed June 5, 1995 (the "'960 application"), presently pending. A copy of references **A01-A17, B01-B28, and C01-C55** can be found in the '960 application file and, pursuant to 37 C.F.R. § 1.98(d)(1), is not enclosed. Applicants would provide the Examiner with a copy of references **A01-A17, B01-B28, and C01-C55**, however, upon request. A copy of references **A18, C56, C57 and C58** is submitted herewith. Identification of the listed references is not to be construed as an admission that such references are available as "prior art" against the subject application.

Applicants wish to inform the Examiner that the '960 application had been involved in: (a) Interference No. 104,396, in which priority of invention was awarded against Cheng, a co-inventor of the presently claimed subject matter; and (b) Interference No. 104,523, in which priority of invention was awarded against Furman, the party adverse to Cheng in that interference.


The presently claimed subject matter is patentably distinct from that of Interference No. 104,396 and Interference No. 104,523.

Applicants respectfully request that the Examiner review all the references identified on the attached form PTO-1449 and make them of record in the file history of the above-identified application.

As this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits (37 C.F.R. § 1.97(b)), Applicants estimate that no fee is required. Should a fee be required, please charge the required fee to Pennie & Edmonds Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Date September 4, 2003

Respectfully submitted,



Matthew E. Langer

36,343

(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.

6523-038

APPLICATION NO

TBA

APPLICANT

Cheng et al.

FILING DATE

September 4, 2003

GROUP

TBA

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|-----|-----------------|----------|------------------|-------|----------|-------------------------------|
| | A01 | 4,000,137 | 12/28/76 | Dvnoch et al. | | | |
| | A02 | 4,336,381 | 6/22/82 | Nagata et al. | | | |
| | A03 | 4,861,759 | 8/29/89 | Mitsuya et al. | | | |
| | A04 | 4,879,277 | 11/7/89 | Mitsuya et al. | | | |
| | A05 | 4,916,122 | 4/10/90 | Chu et al. | | | |
| | A06 | 4,963,533 | 10/16/90 | de Clercq et al. | | | |
| | A07 | 5,047,407 | 9/10/91 | Belleau et al. | | | |
| | A08 | 5,059,690 | 10/22/91 | Zahler et al. | | | |
| | A09 | 5,071,983 | 12/10/91 | Koszalka et al. | | | |
| | A10 | 5,179,104 | 1/12/93 | Chu et al. | | | |
| | A11 | 5,185,437 | 2/9/93 | Koszalka et al. | | | |
| | A12 | 5,204,466 | 4/20/93 | Liotta et al. | | | |
| | A13 | 5,210,085 | 5/11/93 | Liotta et al. | | | |
| | A14 | 5,248,776 | 9/28/93 | Chu et al. | | | |
| | A15 | 5,532,246 | 7/02/96 | Belleau et al. | | | |
| | A16 | 5,539,116 | 7/23/96 | Liotta et al. | | | |
| | A17 | 5,587,480 | 12/24/96 | Belleau et al. | | | |
| | A18 | 6,350,753 | 2/26/02 | Belleau et al. | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|-----|-----------------|----------|---------|-------|----------|-------------|----|
| | | | | | | | YES | NO |
| | B01 | EP 206 497 B1 | 7/20/94 | EP | | | | |
| | B02 | EP 302 760 B1 | 7/29/92 | EP | | | | |
| | B03 | EP 337 713 A2 | 10/18/89 | EPO | | | | |
| | B04 | EP 375 329 A2 | 6/27/90 | EPO | | | | |
| | B05 | EP 382 526 A2 | 8/16/90 | EPO | | | | |
| | B06 | EP 433 898 A | 6/26/91 | EPO | | | | |

| | | | | | | | | |
|--|-----|---------------|----------|-----|--|--|--|--|
| | B07 | EP 494 119 A1 | 7/8/92 | EPO | | | | |
| | B08 | EP 515 144 A1 | 5/19/92 | EPO | | | | |
| | B09 | EP 515 156 A1 | 11/25/92 | EP | | | | |
| | B10 | EP 515 157 A1 | 11/25/92 | EPO | | | | |
| | B11 | EP 526 253 A1 | 2/3/93 | EPO | | | | |
| | B12 | GB 9009861.7 | 11/14/91 | GB | | | | |
| | B13 | GB 9100039.8 | 7/23/92 | GB | | | | |
| | B14 | GB 9109506.7 | 11/12/92 | GB | | | | |
| | B15 | GB 9109913.5 | 7/23/92 | GB | | | | |
| | B16 | GB 9111902.4 | 12/10/92 | GB | | | | |
| | B17 | WO 90/12023 | 10/18/90 | PCT | | | | |
| | B18 | WO 91/11186 | 8/8/91 | PCT | | | | |
| | B19 | WO 91/11186 | 8/8/91 | PCT | | | | |
| | B20 | WO 91/17159 | 11/14/91 | PCT | | | | |
| | B21 | WO 92/10496 | 6/25/92 | PCT | | | | |
| | B22 | WO 92/10497 | 6/25/92 | PCT | | | | |
| | B23 | WO 92/11852 | 7/23/92 | PCT | | | | |
| | B24 | WO 92/14743 | 9/3/92 | PCT | | | | |
| | B25 | WO 92/15308 | 9/17/92 | PCT | | | | |
| | B26 | WO 92/18517 | 10/29/92 | PCT | | | | |
| | B27 | WO 92/19246 | 11/12/92 | PCT | | | | |
| | B28 | WO 92/21676 | 12/10/92 | PCT | | | | |
| | | | | | | | | |

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|-----|---|
| | C01 | Balzarini et al., 1986, "Potent and selective ant-HTLV-III/LAV activity of 2',3'-dideoxycytidine, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine", Biochem Biophys Res Comm 140(2):735-742. |
| | C02 | Belleau et al., 1989, "Design and activity of a novel class of nucleoside analogs effective against HIV-1", 5th International Conference on AIDS, Montreal, Canada, June 4-9, 1989. |
| | C03 | Carter et al., 1990, "Activities of (-)-carbovir and 3'azido-3'deoxythymidine against human immunodeficiency virus in vitro", Antimicrob Agents Chemother 34(6):1297-1300. |
| | C04 | Chang et al., 1987, "Production of hepatitis B virus <i>in vitro</i> by transient expression of cloned HBV DNA in a hepatoma cell line", EMBO J 6(3):675-680. |
| | C05 | Chang et al., 1992, "Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication", J Biol Chem 267:13938-13942. |

| | |
|-----|--|
| C06 | Chen and Cheng, 1989, "Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine", <i>J Biol Chem</i> 264(20):11934-11937. |
| C07 | chromatograph alleging to show that BCH-189 was separated into its individual enantiomers using a chiral triacetylcellulose column (see Third Supplemental Information Disclosure Statement under 37 C.F.R. § 1.56) |
| C08 | Chu et al., 1988, "An efficient total synthesis of 3'-azido-3'-deoxythymidine (AZT) and 3'-azido-2',3'-dideoxyuridine (AZDDU, CS-87) from <u>D</u> -mannitol", <i>Tetrahedron Letters</i> 29(42):5349-5352. |
| C09 | Chu et al., 1988, "Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells", <i>Biochem Pharmacol</i> 37(19):3543-3548. |
| C10 | Chu et al., 1989, "Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells", <i>J Med Chem</i> 32:612-617. |
| C11 | Cretton et al., 1991, "Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells", <i>Mol Pharmacol</i> 39:258-266. |
| C12 | Cretton et al., 1991, "Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in Rhesus monkeys", <i>Antimicrob Agents Chemother</i> 35(5):801-807. |
| C13 | Di Bisceglie et al., 1988, "Hepatocellular carcinoma", <i>Ann Intern Med</i> 108:390-401. |
| C14 | Doong et al., 1991, "Inhibition of the replication of hepatitis B virus <i>in vitro</i> by 2',3'-dideoxy-3'-thiacytidine and related analogues", <i>Proc Natl Acad Sci</i> 88:8495-8499. |
| C15 | E.L. Eliel, <i>Stereochemistry of Carbon Compounds</i> 31-86 (1962) |
| C16 | F.A. Farraye et al., "Preliminary Evidence that Azidothymidine does not Affect Hepatitis B Virus Infection in Acquired Immunodeficiency Syndrome (AIDS) Patients," <i>J. Med. Virol.</i> 29:266-67 (1989) |
| C17 | Furman et al., 1992, "The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the the (-) and (+) enantiomers of <i>cis</i> -5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine", <i>Antimicrob Agents Chemother</i> 36(12):2686-2692. |
| C18 | Ganem and Varmus, "The molecular biology of the hepatitis B virus", <i>Ann Rev Biochem</i> 56:651-693. |
| C19 | H. Haritani et al., "Effect of 3'-Azido-3'-Deoxythymidine on Replication of Duck Hepatitis B Virus <i>In Vivo</i> and <i>In Vitro</i> ," <i>J. Med. Virol.</i> 29:244-48 (1989) |
| C20 | H.E. Varmus, "A Growing Role for Reverse Transcription," <i>Nature</i> 299:204-205 (1982) |
| C21 | Jeong et al., 1993, "Asymmetric synthesis and biological evaluation of β -L-(2R,5S)- and α -L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents", <i>J Med Chem</i> 36(2):181-195. |
| C22 | Kassianides et al., 1989, "Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine: A potential inhibitor of reverse transcriptase", <i>Gastroenterology</i> 97:1275-1280. |
| C23 | Krenitsky et al., 1983, "3'-amino-2',3'-dideoxyribonucleosides of some pyrimidines: Synthesis and biological activities", <i>J Med Chem</i> 26(6):891-895. |
| C24 | Lee et al., 1989, "In vitro and in vivo comparison of the abilities of purine and pyrimidine 2',3'-dideoxynucleosides to inhibit duck hepadnavirus", <i>Antimicrob Agents Chemother</i> 33(3):336-339. |

| | |
|-----|--|
| C25 | Lin et al., 1987, "Potent and selective <i>in vitro</i> activity of 3'-deoxythymidin-2'ene(3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus", <i>Biochem Pharmacol</i> 36(17):2713-2718. |
| C26 | M. Mahmoudian et al., "Enzymatic Production of Optically Pure (2'R- <i>cis</i>)-2'-deoxy-3'-thiacytidine (3TC, Lamivudine): A potent anti-HIV agent," <i>Enzyme Microb. Technol.</i> 15:749-55 (1993) |
| C27 | Matthes et al., 1990, "Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides", <i>Antimicrob Agents Chemother</i> 34(16):1986-1990. |
| C28 | Memorandum, 1988, "Progress in the control of viral hepatitis: Memorandum from a WHO meeting", <i>Bull WHO</i> 66(4):443-455. |
| C29 | Miller and Robinson, 1986, "Common evolutionary origin of hepatitis B virus and retroviruses", <i>Proc Natl Acad Sci</i> 83:2531-2535. |
| C30 | Mitsuya et al., 1985, "3'-azido-3'deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus <i>in vitro</i> ", <i>Proc Natl Acad Sci</i> 82:7096-7100. |
| C31 | Mitsuya et al., 1987, "Rapid in vitro systems for assessing activity of agents against HTLV-III/LAV", in <u>AIDS: Modern Concepts And Therapeutic Challenges</u> , Broder (ed.), pp. 303-333. |
| C32 | Mitsuya et al., 1990, "Molecular targets for AIDS therapy", <i>Science</i> 249:1533-1544. |
| C33 | Norbeck et al., 1989, "(±)-Dioxolane-T: A new 2',3'-dideoxynucleoside prototype with <i>in vitro</i> activity against HIV", <i>Tetrahedron Letters</i> 30(46):6263-6266. |
| C34 | Okabe et al., 1988, "Synthesis of the dideoxynucleosides ddC and CNT from glutamic acid, ribolactone, and pyrimidine bases", <i>J Org Chem</i> 53(20):4780-4786. |
| C35 | Richman et al., 1987, "The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex", <i>New Engl J Med</i> 317(4):192-197. |
| C36 | S.H. Wilen, <i>Tables of Resolving Agents and Optical Resolutions</i> 3-33 and 141-195 (1972) |
| C37 | Satsumabayashi et al., 1972, "The syntheses of 1,3-oxathiolan-5-one derivatives", <i>Bull Chem Soc Japan</i> 45:913-915. |
| C38 | Schinazi et al., 1992, "Activities of four optical isomers of 2',3'-dideoxy-3'thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes", <i>Antimicrob Agents Chemother</i> 36(3):672-676. |
| C39 | Schinazi et al., 1992, "Insights into HIV chemotherapy", <i>AIDS Research and Human Retroviruses</i> 8(6):963-990. |
| C40 | Schinazi et al., 1992, "Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in Rhesus monkeys", <i>Antimicrob Agents Chemother</i> 36(11):2432-2438. |
| C41 | Schinazi et al., 1992, "Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of <i>cis</i> -5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine", <i>Antimicrob Agents Chemother</i> 36(11):2423-2431. |
| C42 | Schinazi et al., 1992, "Substrate specificity of <i>Escherichia coli</i> thymidine phosphorylase for pyrimidine nucleosides with-anti-human immunodeficiency virus activity", <i>Biochem Pharmacol</i> 44(2):199-204. |
| C43 | Sells et al., 1987, "Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA", <i>Proc Natl Acad Sci</i> 84:1005-1009. |
| C44 | Soudeyns et al., 1991, "Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog", <i>Antimicrob Agents Chemother</i> 35(7):1386-1390. |

| | |
|-----|---|
| C45 | Sterzycki et al., 1990, "Synthesis and anti-HIV activity of several 2'-fluoro-containing pyrimidine nucleosides", J Med Chem 33:2150-2157. |
| C46 | Storer et al., 1993, "The resolution and absolute stereochemistry of the enantiomers of <i>cis</i> -1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (BCH189): Equipotent anti-HIV agents", Nucleosides and Nucleotides 12(2):225-236. |
| C47 | Sureau et al., 1986, "Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with a cloned circular HBV DNA", Cell 47:37-47. |
| C48 | Tsurimoto et al., 1987, "Stable expression and replication of hepatitis B virus genome in an integrated state in a human hepatoma cell line transfected with the cloned viral DNA", Proc Natl Acad Sci 84:444-448. |
| C49 | Volk (ed.), 1982, "Essentials of Medical Microbiology", pp. 609-618. |
| C50 | Vorbruggen et al., 1981, "Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts", Chem Ber 114:1234-1255. |
| C51 | W.H. Pirkle et al., "Chiral Stationary Phases for the Direct LC Separation of Enantiomers," (<i>journal title and date unavailable</i>); pp 73-127 |
| C52 | Wilson et al., 1990, "A general method for controlling glycosylation stereochemistry in the synthesis of 2'-deoxyribose nucleosides", Tetrahedron Letters 13:1815-1818. |
| C53 | Wilson et al., 1993, "The synthesis and anti-HIV activity of pyrimidine dioxolanyl nucleosides", Bioorg Med Chem Letters 3(2):169-174. |
| C54 | Yokota et al., 1990, "Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro", Antimicrob Agents Chemother 34(7):1326-1330. |
| C55 | Zhu et al., 1991, "Cellular metabolism of 3'-azido-2',3'-dideoxyuridine with formation of 5'-O-diphosphohexose derivatives by previously unrecognized metabolic pathways for deoxyuridine analogs", Mol Pharmacol 38:929-938. |
| C56 | Skalski et al., 1993, The biochemical basis for the differential anti-human immunodeficiency virus activity of two <i>cis</i> enantiomers of 2',3'-dideoxy-3'-thiacytidine. J Biol Chem. 268(31):23234-8 |
| C57 | De Clercq E. 1995, Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem. 38(14):2491-517. Review |
| C58 | Bastow et al. 1983, Susceptibility of phosphonoformic acid-resistant herpes simplex virus variants to arabinosylnucleosides and aphidicolin. Antimicrob Agents Chemother. 1983 Jun;23(6):914-7 |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.